Author Correction: Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer

A correction has been issued regarding an article published in Nature titled “Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer.” The correction addresses discrepancies in authorship and affiliations among the researchers involved. The original article was authored by Timothy P. Heffernan, who currently resides at C4 Therapeutics in Cambridge, Massachusetts, USA. Lynda Chin, another co-author, is now affiliated with the Institute for Health Transformation at The University of Texas System in Austin, Texas, USA. Both Heffernan and Chin contributed equally to the research. The paper was led by Alessandro Carugo, James Tepper, Frederick Scott Robinson, and Liren Li, with additional contributions from numerous other scientists across multiple institutions. The study, conducted primarily at The University of Texas MD Anderson Cancer Center in Houston, Texas, involved researchers from several departments including Genomic Medicine, Applied Cancer Science, and others. Collaborators included Giannicola Genovese, Maria Svelto, Luigi Nezi, Denise Corti, Rosalba Minelli, Piergiorgio Pettazzoni, Tony Gutschner, Chia-Chin Wu, Sahil Seth, Kadir Caner Akdemir, Samirkumar Amin, Koichi Takahashi, Andrea Viale, Giulio F. Draetta, and Lynda Chin. Additional contributors were based at institutions such as the European Institute of Oncology in Milan, Italy; Sun Yat-Sen University Cancer Center in Guangzhou, China; and the Istituto di Patologia Generale at the Catholic University of Sacred Heart in Rome, Italy. The research team also included experts from the Graduate program in Structural and Computational Biology and Molecular Biophysics at Baylor College of Medicine, the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins University in Baltimore, Maryland, and the Department of Molecular and Cellular Oncology at MD Anderson. Other participants came from the Department of Translational Molecular Pathology, the Department of Leukemia, the Office of Technology Commercialization, the Department of Cancer Systems Imaging, the Department of Cancer Biology, the Department of Experimental Therapeutics, the ORBIT Platform, and the Department of Surgical Oncology, all within MD Anderson. International collaborators included Abbas Agaimy from Friedrich Alexander University Erlangen-Nuremberg, University Hospital in Erlangen, Germany, and Anirban Maitra and Huamin Wang from MD Anderson. Charles W. M. Roberts from St Jude Children’s Research Hospital in Memphis, Tennessee, also played a role in the study. The work focused on identifying synthetic vulnerabilities within specific subpopulations of mesenchymal cells found in pancreatic tumors. These vulnerabilities could potentially serve as targets for more effective therapeutic strategies against this aggressive form of cancer. The findings were part of broader efforts to understand how different cellular components contribute to tumor progression and resistance to treatment. The corrected information clarifies the affiliations and roles of each researcher, ensuring accurate representation of their contributions. This clarification comes amid ongoing discussions about the complexities of authorship in large-scale collaborative scientific projects, particularly in fields like oncology where multidisciplinary teams often play critical roles in advancing knowledge and developing new treatments. The study continues to be reviewed by the scientific community, with further insights expected as follow-up research progresses. Researchers remain committed to refining their understanding of pancreatic cancer biology and exploring novel approaches to improve patient outcomes.